Malvern Instruments has published a new application note examining the use of NanoSight Nanoparticle Tracking Analysis (NTA) ...

Lyndra Therapeutics has announced the immediate appointment of Adam Sayer as its new president and CEO, succeeding Jessica ...

AstraZeneca and Daiichi Sankyo ’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from ...

The FDA has granted RMAT designation to Beacon Therapeutics’ gene therapy, laru-zova, for treating X-linked retinitis pigmentosa (XLRP).

The deal includes an upfront payment of $250m, with the potential for an additional $752.5m in milestone payments.

The new indication makes Ozempic the first glucagon-like peptide-1 receptor agonist (GLP-1RA) available for people with T2D ...

Sonnet BioTherapeutics has received a patent from the European Patent Office (EPO) for its fully human albumin binding (FHAB) technology.

A proposed ban on PFAS chemicals is being challenged over concerns about potential supply chain disruption in the ...

ITM Radiopharma’s Phase III trial of its targeted radiotherapeutic for patients with Grade 1 or 2 gastroenteropancreatic ...

A year after reducing half of its workforce, Allakos will downsize to just 15 employees as it halts the development of AK006.

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

Can-Fite BioPharma has secured a US patent for Namodenoson, its lead drug candidate, for use as an anti-obesity treatment.